--- title: "TRIUMPH-4: Retatrutide Phase 3 Results | Primara Labs" url: https://www.primaralabs.com/research/trials/triumph-4 source: Primara Labs, markdown mirror of the HTML page --- # TRIUMPH-4 In TRIUMPH-4, a phase 3 trial of retatrutide in adults with obesity or overweight and knee osteoarthritis, without diabetes (n=445), mean body weight fell 26.4% on 9 mg and 28.7% on 12 mg over 68 weeks, against 2.1% on placebo (efficacy estimand; Eli Lilly topline release, 11 December 2025). Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked. Updated 24 September 2026 Retatrutide Explained: Triple Agonist Research (Philippines Guide)1:50·[Transcript and chapters](https://www.primaralabs.com/videos/retatrutide) ## Results Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ. WOMAC pain fell 4.5 and 4.4 points from a baseline of 6.0 on 9 and 12 mg, against 2.4 on placebo. ## Side effects reported In TRIUMPH-4, discontinuation because of adverse events was 12.2% on 9 mg and 18.2% on 12 mg, against 4.0% on placebo. The most frequently reported adverse events were nausea in 38.1% on 9 mg and 43.2% on 12 mg against 10.7% on placebo, diarrhoea in 34.7% on 9 mg and 33.1% on 12 mg against 13.4% on placebo, constipation in 21.8% on 9 mg and 25.0% on 12 mg against 8.7% on placebo and vomiting in 20.4% on 9 mg and 20.9% on 12 mg against 0.0% on placebo. | Event | 9 mg | 12 mg | Placebo | | --- | --- | --- | --- | | Discontinuation for adverse events | 12.2% | 18.2% | 4.0% | | Nausea | 38.1% | 43.2% | 10.7% | | Diarrhoea | 34.7% | 33.1% | 13.4% | | Constipation | 21.8% | 25.0% | 8.7% | | Vomiting | 20.4% | 20.9% | 0.0% | | Decreased appetite | 19.0% | 18.2% | 9.4% | | Dysesthesia | 8.8% | 20.9% | 0.7% | Design ## Trial design and sources Compound Retatrutide Phase 3 Population Adults with obesity or overweight and knee osteoarthritis, without diabetes Participants randomised 445 Duration 68 weeks Primary endpoint Co-primary: percent change in body weight and change in WOMAC pain score at 68 weeks Estimand efficacy Read out 11 December 2025 - Eli Lilly topline release, 11 December 2025 [open](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) · checked 23 September 2026 - ClinicalTrials.gov NCT05931367 [open](https://clinicaltrials.gov/study/NCT05931367) · checked 23 September 2026 - Registry: NCT05931367 Questions ## TRIUMPH-4, answered ### What did TRIUMPH-4 find? In TRIUMPH-4, a phase 3 trial of retatrutide in adults with obesity or overweight and knee osteoarthritis, without diabetes (n=445), mean body weight fell 26.4% on 9 mg and 28.7% on 12 mg over 68 weeks, against 2.1% on placebo (efficacy estimand; Eli Lilly topline release, 11 December 2025). ### What side effects were reported in TRIUMPH-4? In TRIUMPH-4, discontinuation because of adverse events was 12.2% on 9 mg and 18.2% on 12 mg, against 4.0% on placebo. The most frequently reported adverse events were nausea in 38.1% on 9 mg and 43.2% on 12 mg against 10.7% on placebo, diarrhoea in 34.7% on 9 mg and 33.1% on 12 mg against 13.4% on placebo, constipation in 21.8% on 9 mg and 25.0% on 12 mg against 8.7% on placebo and vomiting in 20.4% on 9 mg and 20.9% on 12 mg against 0.0% on placebo. Related ## More on retatrutide - [TRIUMPH-1](https://www.primaralabs.com/research/trials/triumph-1) - [TRIUMPH-2](https://www.primaralabs.com/research/trials/triumph-2) - [TRIUMPH-3](https://www.primaralabs.com/research/trials/triumph-3) - [Retatrutide phase 2 (Jastreboff)](https://www.primaralabs.com/research/trials/retatrutide-phase-2) - [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5) - [TRIUMPH-6](https://www.primaralabs.com/research/trials/triumph-6) - [TRIUMPH-7](https://www.primaralabs.com/research/trials/triumph-7) - [TRIUMPH-8](https://www.primaralabs.com/research/trials/triumph-8) - [TRIUMPH-9](https://www.primaralabs.com/research/trials/triumph-9) - [TRIUMPH-OUTCOMES](https://www.primaralabs.com/research/trials/triumph-outcomes) - [Evidence Map: Retatrutide](https://www.primaralabs.com/research/evidence#retatrutide) - [Retatrutide 20mg](https://www.primaralabs.com/marketplace/retatrutide) ## More videos Retatrutide vs Tirzepatide vs Semaglutide: Trials Compared (PH)1:55·[Transcript and chapters](https://www.primaralabs.com/videos/reta-vs-tirz-vs-sema)